Valuation: Insmed Incorporated

Market Cap 26.58B 24.09B 22.28B 20.1B 37.88B 2,506B 39.22B 268B 106B 1,339B 99.75B 97.63B 4,250B P/E 2026 *
-73.9x
P/E 2027 * 170x
Enterprise Value 26.07B 23.62B 21.85B 19.71B 37.15B 2,458B 38.46B 262B 104B 1,313B 97.82B 95.74B 4,167B EV / Sales 2026 *
14x
EV / Sales 2027 * 8.57x
Free-Float
99.48%
Yield 2026 *
-
Yield 2027 * -
1 day+2.62%
1 week+5.90%
Current month+7.62%
1 month+22.12%
3 months-2.09%
6 months+11.01%
Current year-30.38%
1 week 113.8
Extreme 113.805
121.54
1 month 92.62
Extreme 92.625
121.54
Current year 90.39
Extreme 90.39
186.19
1 year 90.39
Extreme 90.39
212.75
3 years 21.92
Extreme 21.92
212.75
5 years 16.04
Extreme 16.04
212.75
10 years 11.31
Extreme 11.31
212.75
Manager TitleAgeSince
Chief Executive Officer 57 2012-09-09
Chief Tech/Sci/R&D Officer 62 2019-12-18
Chief Operating Officer 57 2019-11-13
Director TitleAgeSince
Chairman 75 2009-06-15
Chairman 57 2018-11-07
Director/Board Member 72 2014-05-28
Date Insider Type Main position Quantity % Market Cap. Importance
10/19/26 Free

Director

6,139 0.0028%
10/19/26 Free

Director

6,139 0.0028%
9/9/26 Sell

Director

-25,000 0.0114%
Change 5-day change 1-year change 3-year change Capi.($)
+2.62%+5.90%-37.29%+386.59% 26.58B
-2.69%-0.48%+53.97%+66.82% 66.33B
-0.92%+7.67%+12.64%+93.22% 60.62B
0.00%+0.39%+22.34%+89.58% 55.5B
+0.14%+2.35%+13.86%+111.94% 47.58B
-2.21%-2.47%+20.18%+28.81% 43.69B
-2.30%-10.40%+154.30%+707.36% 37.27B
+2.15%+1.42%+14.58%+48.71% 36.57B
-2.32%-2.24%+76.50%+56.02% 32.22B
-0.77%-5.11%+43.45%-2.79% 24.45B
Average -0.62%-0.14%+37.45%+158.63% 43B
Weighted average by Cap. -0.82%+0.08%+37.02%+143.44%

Financials

2026 *2027 *
Net sales 1.86B 1.69B 1.56B 1.41B 2.65B 176B 2.75B 18.74B 7.43B 93.75B 6.99B 6.84B 298B 2.99B 2.71B 2.51B 2.26B 4.26B 282B 4.42B 30.13B 11.95B 151B 11.23B 10.99B 478B
Net income -357M -324M -300M -270M -509M -33.69B -527M -3.6B -1.43B -18B -1.34B -1.31B -57.13B 167M 152M 140M 127M 239M 15.79B 247M 1.69B 668M 8.43B 628M 615M 26.77B
Net Debt -514M -466M -431M -389M -733M -48.51B -759M -5.18B -2.05B -25.91B -1.93B -1.89B -82.25B -949M -860M -795M -718M -1.35B -89.48B -1.4B -9.56B -3.79B -47.8B -3.56B -3.49B -152B
Projected Income Statement - Annual - Insmed Incorporated
Logo Insmed Incorporated
Insmed Incorporated is a global biopharmaceutical company. It is advancing a diverse range of approved and mid- to late-stage investigational medicines and drug discovery. Its advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. Its pre-clinical research programs encompass a range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Its first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib, TPIP, and INS1201 and pre-clinical research programs. Its INS1148 is an investigational monoclonal antibody.
Employees
1,664
Date Price Change Volume
26-11-13 US$121.16 +2.62% 1,543,624
26-11-12 US$118.07 -2.22% 2,397,944
26-11-11 US$120.75 +1.05% 1,488,927
26-11-10 US$119.49 +2.92% 3,346,741
26-11-09 US$116.10 +1.48% 2,668,854
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Insmed Incorporated
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
121.16USD
Average target price
194.18USD
Spread / Average Target
+60.27%
  1. Stock Market
  2. Stocks
  3. INSM Stock